XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.24.3

Note 9 - Concentrations of Credit Risk | 9 Months Ended
--- | ---
Sep. 30, 2024
Notes to Financial Statements |
Concentration Risk Disclosure [Text Block] | Note 9. Concentrations of credit risk The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by changes in government regulations. Most of the Company’s borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the loans. The Company’s largest debt investments may vary from period to period as new debt investments are recorded and existing debt investments are repaid. The Company’s five largest debt investments at cost represented 22% and 23% of total debt investments outstanding as of September 30, 2024 and December 31, 2023, respectively. The Company’s five largest debt investments at fair value represented 23% and 22% of total debt investments outstanding as of September 30, 2024 and December 31, 2023, respectively. No single debt investment represented more than 10% of the total debt investments at cost or fair value as of September 30, 2024 and December 31, 2023. Investment income, consisting of interest and fees, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments at cost accounted for 21% and 24% of total interest and fee income on investments for the three months ended September 30, 2024 and 2023, respectively. Interest income from the five largest debt investments at fair value accounted for 25% and 22% of total interest and fee income on investments for the three months ended September 30, 2024 and 2023, respectively. Interest income from the five largest debt investments at cost accounted for 21% and 23% of total interest and fee income on investments for the nine months ended September 30, 2024 and 2023, respectively. Interest income from the five largest debt investments at fair value accounted for 23% and 21% of total interest and fee income on investments for the nine months ended September 30, 2024 and 2023, respectively.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration